autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes

Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes is a cell-based gene therapy developed by the National Cancer Institute (NCI) for the treatment of metastatic melanoma. The therapy involves isolating tumor-infiltrating lymphocytes (TILs) or peripheral blood lymphocytes (PBLs) from a patient and genetically modifying them using a retroviral vector to express the F5 T-cell receptor (TCR). This specific TCR, derived from the DMF5 clone, is engineered to recognize the MART-1 (Melanoma Antigen Recognized by T cells) protein, a common melanoma-associated antigen, when presented by HLA-A*0201. Following ex vivo expansion, the engineered cells are reinfused into the patient after a lymphodepleting conditioning regimen (typically cyclophosphamide and fludarabine). High-dose interleukin-2 (IL-2) is subsequently administered to support the expansion and persistence of the infused T cells in vivo.

Other names

anti-MART-1 F5 TCR-engineered lymphocytesanti-MART1 F5 TCR-engineered lymphocytesanti-MART 1 F5 TCR-engineered lymphocytesMART-1 F5 TCR TILMART1 F5 TCR TILMART 1 F5 TCR TILF5 TCR-engineered T cellsF-5 TCR-engineered T cellsF 5 TCR-engineered T cells